Expert eValuation of Efficacy and Rationality of Vildagliptin "EVER-Vilda": An Indian Perspective.
Sanjay KalraAbdul Hamid ZargarG R SridharAshok Kumar DasJamal AhmedJagdish Chander MohanG VijayakumarAjay KumarRakesh Kumar SahayVageesh AyerKaushik PanditGanapathi BantwalArun SrinivasA G UnnikrishnanSushil JindalSaumitra RayManash P BaruahKajal GangulySachin MittalAmeya JoshiJoe GeorgeGanesh HkNitin KapoorSantosh RamakrishnanChetan ShahAtul DhingraBalram SharmaPublished in: Clinical medicine insights. Endocrinology and diabetes (2024)
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy.
Keyphrases
- combination therapy
- glycemic control
- type diabetes
- end stage renal disease
- primary care
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- physical activity
- body mass index
- clinical practice
- metabolic syndrome
- peritoneal dialysis
- patient reported outcomes
- mesenchymal stem cells
- machine learning
- functional connectivity
- patient reported
- resting state
- body weight